Evercore ISI upgraded Mesa Labs to Outperform from In Line with a price target of $125, up from $100. While the Life Science & Diagnostic Tools group has run up on potential biopharma turnaround, Mesa shares have lagged, notes the analyst. With biopharma consumables growing quarter-over-quarter, the firm thinks Mesa Labs “is a catch up trade,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MLAB: